Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.79 |
| ▸ | CTSS | P25774 | 3/20 | 0.58 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047492 | 0.96 | CTSK (0.74) | CTSKCTSSCCR1ACE2MEN1 | |
| SCHEMBL4041000 | 0.96 | CTSK (0.73) | CTSKCTSSCCR1ACE2MEN1 | |
| SCHEMBL4038740 | 0.96 | CTSK (0.73) | CTSKCTSSCCR1ACE2MEN1 | |
| SCHEMBL4042018 | 0.95 | CTSK (0.75) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4038286 | 0.95 | CTSK (0.72) | CTSKCTSSCCR1ACE2MEN1 | |
| SCHEMBL4048700 | 0.94 | CTSK (0.73) | CTSKCTSSCCR1 | |
| SCHEMBL4040527 | 0.94 | CTSK (0.73) | CTSKCTSSCCR1CTSVCTSL | |
| SCHEMBL4037118 | 0.92 | CTSK (0.71) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4039416 | 0.92 | CTSK (0.78) | CTSKCTSSCCR1MEN1ALDH1A1 | |
| SCHEMBL4045117 | 0.92 | CTSK (0.70) | CTSKCTSSCTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | BAYER SCHERING PHARMA AG (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-2020404-A1 | Cyanomethyl substituted N-Acyl Tryptamines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-02-04 | — | — | EP | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CTSK 1880/4885CTSS 3389/4885CCR1 1957/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | CTSK 2460/4885CTSS 2896/4885CCR1 475/4885 |
| US-20090069321-A1 | CYANOMETHYL SUBSTITUTED N-ACYL TRYPTAMINES | FSHR, GNRHR, HNMT | CTSK 248/4885CTSS 209/4885CCR1 2015/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CCR1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.